Neuren Pharmaceuticals Limited
NURPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.33 | 0.00 | -0.92 | 0.06 |
| FCF Yield | 7.43% | 0.58% | -0.75% | 4.42% |
| EV / EBITDA | 157.79 | 9.11 | 669.59 | 20.88 |
| Quality | ||||
| ROIC | -0.94% | 34.44% | -4.27% | 46.60% |
| Gross Margin | 47.32% | 92.17% | 26.46% | 90.73% |
| Cash Conversion Ratio | 8.54 | 0.07 | -2.56 | 1.28 |
| Growth | ||||
| Revenue 3-Year CAGR | 599.10% | 618.07% | 165.41% | 157.21% |
| Free Cash Flow Growth | 1,285.69% | 145.08% | -114.67% | 212.14% |
| Safety | ||||
| Net Debt / EBITDA | -0.54 | -0.02 | -0.63 | -0.11 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.98 | 0.00 | 0.00 |
| Cash Conversion Cycle | 25.06 | 156.57 | 32.49 | 3.80 |